ArticleLung cancer (Amsterdam, Netherlands)2023

Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer.

Sheena Bhalla et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.